AstraZeneca shares tumbled on Thursday after the company said its nerve disease drug Wainua, made in partnership with U.S.-based Ionis, failed to meet the main goal of reducing cardiovascular deaths and recurring heart problems in a late-stage trial.
The setback dims what some analysts predicted could be a $2 billion peak-sales opportunity for Wainua, as the Anglo-Swedish drugmaker aims for $80 billion in annual revenue by 2030 by launching up to 20 new medicines.
